Bob, I agree in general, but I think their could be substantial news between now and May.
Several partnerships are in discussion, no telling what will come to fruition. The approval of the IND and start of the Phase I/II Trial for N901-DM1. The conclusion of the Single Dose Trial and Milestone Payment for completing it. Possible Milestones from the agreements with DNA and/or ABGX, probably for the conjugation of new drugs and initiation of preclinical trials.
No doubt there are others, but perhaps the biggest thing that could happen would be meeting the rumored milestone for 50% tumor shrinkage. Numerous knowledgeable and credible posters believe this milestone exists, no one knows the criteria, but if the conditions are met before May, efficacy will be established before Dr. Schilsky's presentation. This should not detract from his presentation, it should actually enhance it as most everyone at the conference will know that the drug's working, they'll want to attend his presentation to learn just how well.
I believe the price will stabilize and gradually return to prior highs as more becomes known, but I also believe the Biotech Sector will also become favored again in time. For now we're moving with the sector and lack of anticipated news.
Gary |
